NCT02337829 2026-01-08Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLAcerta Pharma BVPhase 2 Completed48 enrolled 12 charts
NCT02296918 2025-12-19Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLAcerta Pharma BVPhase 1 Completed69 enrolled
NCT04930536 2024-11-22Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaAstraZenecaPhase 4 Completed103 enrolled 10 charts
NCT03788291 2024-09-26Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaUniversity of RochesterPhase 2 Completed39 enrolled 8 charts